C12N 2310/3341
5-methylcytosine
Official title: 5-Methylcytosine
C12N2310/3341 (5-methylcytosine) appears on 974 US grants and 2,021 published applications in this corpus.
Search patents in C12N- Granted patents
- 974
- Published applications
- 2,021
- Assignees
- 321
- Inventors
- 1,640
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1995 | 2 | 0 |
| 1996 | 1 | 0 |
| 1997 | 1 | 0 |
| 1998 | 4 | 0 |
| 1999 | 17 | 0 |
| 2000 | 49 | 0 |
| 2001 | 47 | 4 |
| 2002 | 53 | 20 |
| 2003 | 22 | 170 |
| 2004 | 20 | 218 |
| 2005 | 14 | 81 |
| 2006 | 9 | 40 |
| 2007 | 11 | 34 |
| 2008 | 15 | 23 |
| 2009 | 23 | 42 |
| 2010 | 29 | 41 |
| 2011 | 23 | 49 |
| 2012 | 35 | 55 |
| 2013 | 35 | 53 |
| 2014 | 49 | 62 |
| 2015 | 45 | 81 |
| 2016 | 46 | 72 |
| 2017 | 47 | 73 |
| 2018 | 40 | 92 |
| 2019 | 47 | 82 |
| 2020 | 50 | 90 |
| 2021 | 50 | 104 |
| 2022 | 46 | 97 |
| 2023 | 37 | 107 |
| 2024 | 34 | 118 |
| 2025 | 45 | 124 |
| 2026 | 28 | 89 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Compounds and methods for reducing PLN expression22 Sep 2026US 12,742,170 B2Ionis Pharmaceuticals, Inc.
- Compounds and methods for reducing FUS expression15 Sep 2026US 12,735,700 B2Ionis Pharmaceuticals, Inc.
- Oligonucleotide compositions and methods of use thereof15 Sep 2026US 12,735,703 B2Wave Life Sciences Ltd.
- Modulation of GYS1 expression25 Aug 2026US 12,716,067 B2Ionis Pharmaceuticals, Inc.
- Muscle targeting complexes and formulations for treating myotonic dystrophy4 Aug 2026US 12,697,394 B2Dyne Therapeutics, Inc.
- Methods of treatment of chronic kidney disease8 Oct 2026US 2026/0308590 A1AstraZeneca AB
- Antisense oligomer formulations8 Oct 2026US 2026/0308595 A1Stoke Therapeutics, Inc.
- Oligonucleotides comprising segmented gap structures1 Oct 2026US 2026/0297584 A1Ausperbio Therapeutics Inc.
- Modulation of Dystrophia Myotonica-Protein Kinase (DMPK) Expression1 Oct 2026US 2026/0297587 A1Ionis Pharmaceuticals, Inc.
- Modified iscb nucleases, modified guide rnas, and uses thereof24 Sep 2026US 2026/0286324 A1Aera Therapeutics, Inc.
Most cited
By later US patents
- Oligoribonucleotides and ribonucleases for cleaving RNA486US 6,107,094 AIsis Pharmaceuticals, Inc. · 2000
- Oligoribonucleotides for cleaving RNA385US 5,898,031 AIsis Pharmaceuticals, Inc. · 1999
- RNA containing modified nucleosides and methods of use thereof353US 8,278,036 B2The Trustees of the University of Pennsylvania · 2012
- Modulation of apolipoprotein C-III expression262US 7,598,227 B2Isis Pharmaceuticals, Inc. · 2009
- Alteration of cellular behavior by antisense modulation of mRNA processing259US 6,210,892 B1Isis Pharmaceuticals, Inc. · 2001